Effects of Atorvastatin on Coronary Flow Reserve in Patients with Slow Coronary Flow
| Autor: | Hakan Gullu, Mustafa Caliskan, Aylin Yildirir, Haldun Muderrisoglu, Semra Topcu, Dogan Erdogan, Ozgur Ciftci |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Atorvastatin Clinical Investigations Hemodynamics Coronary Artery Disease Doppler echocardiography Coronary Angiography Coronary artery disease Coronary Circulation Internal medicine medicine Humans Pyrroles Prospective Studies Endothelial dysfunction Triglycerides Aged medicine.diagnostic_test business.industry Anticholesteremic Agents Cholesterol HDL nutritional and metabolic diseases Coronary flow reserve Cholesterol LDL General Medicine Middle Aged medicine.disease Echocardiography Doppler Dipyridamole Cholesterol Heptanoic Acids Cardiology Female lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business TIMI medicine.drug |
| Zdroj: | Clinical Cardiology. 30:475-479 |
| ISSN: | 1932-8737 0160-9289 |
| DOI: | 10.1002/clc.20140 |
| Popis: | Background Statins improve endothelial functioning in patients with coronary artery disease and hypercholesterolemia, while substantially little is known about induced changes in myocardial microcirculation. However, although previous studies have suggested that microvascular abnormalities and endothelial dysfunction is responsible for slow coronary flow (SCF), there is no study investigating possible effects of statins on coronary microvascular function in patients with SCF. Hypothesis We prospectively investigated the effects of short-term lipid-lowering therapy with atorvastatin on coronary flow reserve (CFR) reflecting coronary microvascular function in patients with SCF assessed by transthoracic Doppler echocardiography (TTDE). Methods In an open clinical trial, CFR was studied in 20 subjects with SCF. TTDE was used to assess CFR at baseline as well as after 8 weeks of atorvastatin therapy. Coronary flow was quantified according to TIMI frame count (TFC). Coronary diastolic peak flow velocities were measured at baseline and after dipyridamole infusion. CFR was calculated as the ratio of hyperemic to baseline diastolic peak velocities. Results CFR was independently correlated with TFC. After 8 weeks of atorvastatin therapy, CFR values increased significantly (1.95 ± 0.38 vs. 2.54 ± 0.56, (p < 0.001). No change in hemodynamic parameters was noted during the entire study. The improvement in CFR was not correlated to the amount of lipid-lowering effect of atorvastatin. Conclusions These findings suggest that short-term lipid-lowering therapy with atorvastatin improved CFR, which reflects coronary microvascular functioning in patients with SCF. Copyright © 2007 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|